HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

AbstractOBJECTIVE:
To test the safety and efficacy of interferon beta-1a (IFN-beta) in treatment-resistant chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
BACKGROUND:
Current treatment regimens leave 4% to 30% of patients with CIDP with moderate or severe disability. IFN-beta has been reported as beneficial in one treatment-resistant patient.
METHODS:
Ten consecutive treatment-resistant patients were randomized in a double-blind, crossover design to receive placebo or IFN-beta (3 MIU for 2 weeks and then 6 MIU for 10 weeks) subcutaneously three times weekly, followed by 4 weeks without treatment, and then the opposite treatment for 12 weeks. The primary outcome measure was "clinically important" improvement by specified amounts in any three of eight clinical measures: timed 10-m walk, Ambulation Index, expanded Medical Research Council sum score, nine-hole peg test time, Functional Independence Measure, Hammersmith Motor Ability, a new Guy's Neurological Disability Scale, and the EuroQoL quality-of-life scale. These and motor median nerve conduction studies were measured before and after 12 weeks of each treatment.
RESULTS:
Clinically important improvement was observed in one patient while taking IFN-beta and two patients while taking placebo. There was no significant difference between IFN-beta and placebo in the change in any of the individual clinical or neurophysiological measures between the beginning and end of treatment. There were no serious adverse events.
CONCLUSION:
This trial shows that IFN-beta is safe but not efficacious in treatment-resistant CIDP.
AuthorsR D Hadden, B Sharrack, S Bensa, S E Soudain, R A Hughes
JournalNeurology (Neurology) Vol. 53 Issue 1 Pg. 57-61 (Jul 13 1999) ISSN: 0028-3878 [Print] United States
PMID10408537 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Adult
  • Age of Onset
  • Aged
  • Chronic Disease
  • Cross-Over Studies
  • Demyelinating Diseases (physiopathology, therapy)
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation
  • Interferon beta-1a
  • Interferon-beta (therapeutic use)
  • Male
  • Median Nerve (physiopathology)
  • Middle Aged
  • Neural Conduction
  • Neurologic Examination
  • Polyradiculoneuropathy (physiopathology, therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: